Literature DB >> 26398200

Protein Aggregation in Frozen Trehalose Formulations: Effects of Composition, Cooling Rate, and Storage Temperature.

Brian D Connolly1, Lan Le2, Thomas W Patapoff2, Mary E M Cromwell3, Jamie M R Moore4, Philippe Lam5.   

Abstract

This study was designed to assess the effects of cooling rate, storage temperature, and formulation composition on trehalose phase distribution and protein stability in frozen solutions. The data demonstrate that faster cooling rates (>100°C/min) result in trehalose crystallization and protein aggregation as determined by Fourier Transform Near-Infrared (FT-NIR) spectroscopy and size-exclusion chromatography, respectively. Conversely, at slower cooling rates (≤1°C/min), trehalose remains predominantly amorphous and there is no effect on protein stability. Evaluation of storage temperatures demonstrates that aggregation increases more rapidly at -14°C compared with higher (-8°C) and lower (-20°C) storage temperatures; however, a relatively higher amount of cumulative aggregation was observed at lower (-20°C) temperature compared with higher storage temperatures (-14°C and -8°C). Further evaluation of the effects of formulation composition suggests that the phase distribution of amorphous and crystallized trehalose dihydrate in frozen solutions depends on the ratio of trehalose to mAb. The results identify an optimal range of trehalose-mAb (w/w) ratio, 0.2-2.4, capable of physically stabilizing mAb formulations during long-term frozen storage-even for fast cooled (>100°C/min) formulations.
© 2015 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  FTIR; crystallization; degradation products; formulation; nucleation; precipitation; protein aggregation; protein formulation; stability; stabilization

Mesh:

Substances:

Year:  2015        PMID: 26398200     DOI: 10.1002/jps.24646

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  5 in total

1.  Characterization of mAb dimers reveals predominant dimer forms common in therapeutic mAbs.

Authors:  Friederike Plath; Philippe Ringler; Alexandra Graff-Meyer; Henning Stahlberg; Matthias E Lauer; Arne C Rufer; Melissa A Graewert; Dmitri Svergun; Gerald Gellermann; Christof Finkler; Jan O Stracke; Atanas Koulov; Volker Schnaible
Journal:  MAbs       Date:  2016-03-31       Impact factor: 5.857

2.  Effects of Excipient Interactions on the State of the Freeze-Concentrate and Protein Stability.

Authors:  Sampreeti Jena; Jacqueline Horn; Raj Suryanarayanan; Wolfgang Friess; Alptekin Aksan
Journal:  Pharm Res       Date:  2016-12-15       Impact factor: 4.200

3.  The effect of mAb and excipient cryoconcentration on long-term frozen storage stability - part 2: Aggregate formation and oxidation.

Authors:  Oliver Bluemel; Jakob W Buecheler; Astrid Hauptmann; Georg Hoelzl; Karoline Bechtold-Peters; Wolfgang Friess
Journal:  Int J Pharm X       Date:  2021-12-25

4.  The effect of mAb and excipient cryoconcentration on long-term frozen storage stability - Part 1: Higher molecular weight species and subvisible particle formation.

Authors:  Oliver Bluemel; Moritz Anuschek; Jakob W Buecheler; Georg Hoelzl; Karoline Bechtold-Peters; Wolfgang Friess
Journal:  Int J Pharm X       Date:  2021-12-25

Review 5.  Armamentarium of Cryoprotectants in Peptide Vaccines: Mechanistic Insight, Challenges, Opportunities and Future Prospects.

Authors:  Harshita Dalvi; Aditi Bhat; Akshaya Iyer; Vaskuri G S Sainaga Jyothi; Harsha Jain; Saurabh Srivastava; Jitender Madan
Journal:  Int J Pept Res Ther       Date:  2021-10-19       Impact factor: 1.931

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.